| scholarly article | Q13442814 |
| P50 | author | George Sakoulas | Q106083571 |
| P2093 | author name string | Pamela A Moise | |
| Avisheh Forouzesh | |||
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| Vancomycin- and erythromycin-induced hearing loss in humans | Q30502734 | ||
| Vancomycin: a history | Q34472263 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| The pharmacokinetic and pharmacodynamic properties of vancomycin | Q36328971 | ||
| Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity | Q36538707 | ||
| Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit | Q36747581 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period | Q41066970 | ||
| Vancomycin Ototoxicity in a Patient with Normal Renal Function | Q42269595 | ||
| Historical yearly usage of vancomycin. | Q42743595 | ||
| Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux | Q43846235 | ||
| Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy | Q44959085 | ||
| Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections | Q45127594 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
| A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia | Q80783502 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ototoxicity | Q1351381 |
| vancomycin | Q424027 | ||
| P304 | page(s) | 483-486 | |
| P577 | publication date | 2008-11-10 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Vancomycin ototoxicity: a reevaluation in an era of increasing doses | |
| P478 | volume | 53 |
| Q47605331 | A Rapid and Simple HPLC Method for Therapeutic Monitoring of Vancomycin |
| Q39375881 | Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals |
| Q43237184 | Antibiotic therapy of vascular catheter-related bloodstream infections: is vancomycin the optimal choice for Staphylococcus aureus infections? |
| Q50434466 | Are gentamicin and/or vancomycin associated with ototoxicity in the neonate? A retrospective audit |
| Q94563595 | Calculated initial parenteral treatment of bacterial infections: Safety and tolerabilty |
| Q61806736 | Catheter-related bloodstream infections with coagulase-negative staphylococci: are antibiotics necessary if the catheter is removed? |
| Q38185097 | Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections |
| Q34157657 | Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children |
| Q91625300 | Common Aminoglycosides and Platinum-Based Ototoxic Drugs: Cochlear/Vestibular Side Effects and Incidence |
| Q41874503 | Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis |
| Q30240026 | Drug-induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies |
| Q43662262 | Evaluation of an institutional guideline for the treatment of cerebrospinal fluid shunt-associated infections. |
| Q34894900 | How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? |
| Q42586724 | Is vancomycin ototoxicity a significant risk? |
| Q39135986 | Neuropsychiatric Effects of Antimicrobial Agents |
| Q42910842 | ORIGINAL ARTICLE: Investigation of the prediction accuracy of vancomycin concentrations determined by patient-specific parameters as estimated by Bayesian analysis |
| Q37811204 | Oral Infections and Antibiotic Therapy |
| Q90618447 | Ototoxicity and Nephrotoxicity With Elevated Serum Concentrations Following Vancomycin Overdose: A Retrospective Case Series |
| Q41723791 | Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring. |
| Q40481176 | Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens. |
| Q35598479 | Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial |
| Q43378543 | Review on Usage of Vancomycin in Livestock and Humans: Maintaining Its Efficacy, Prevention of Resistance and Alternative Therapy. |
| Q38620307 | Staphylococcus epidermidis as a cause of bacteremia |
| Q41447169 | Sustained release of vancomycin from novel biodegradable nanofiber-loaded vascular prosthetic grafts: in vitro and in vivo study |
| Q38068293 | The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. |
| Q40915627 | Therapeutic drug monitoring of antimicrobials |
| Q33881584 | Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections |
| Q37892556 | Vancomycin dosing and monitoring 2 years after the guidelines |
| Q37845424 | Vancomycin dosing in patients on intermittent hemodialysis |
| Q84028205 | [Daptomycin in the treatment of Gram-positive infections in patients with chronic renal failure] |
Search more.